SB 202190
NEW
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
Description: SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38alpha and p38beta2... more
Product information "SB 202190"
Description: SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38alpha and p38beta2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes. Target: Apoptosis, p38 MAPK, Autophagy. Smiles: Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1. References: Nassar K, et al. A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery. J Glaucoma. 2015 Feb,24(2):165-78.
| Keywords: | FHPI, SB202190 |
| Supplier: | TargetMol |
| Supplier-Nr: | T2301 |
Properties
| MW: | 331.34 D |
| Formula: | C20H14FN3O |
Database Information
| CAS : | 152121-30-7| Matching products |
Handling & Safety
| Storage: | -20°C |
| Shipping: | +20°C (International: +4°C) |
| Signal Word: | Warning |
| GHS Hazard Pictograms: |
|
| H Phrases: | H315, H319, H335 |
| P Phrases: | P261, P264, P271, P280, P312, P321, P302+P352, P304+P340, P305+P351+P338, P332+P313, P337+P313, P362+P364, P405, P403+P233, P501 |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
Viewed